Rink is former Chairman and Chief Executive Officer of Aurora Biosciences Corporation, a drug discovery technology company in San Diego, California. He is currently a board member of Cambridge Epigenetix Ltd and Genome Research Ltd. Over the past 20 years, Dr Rink has also served on the boards of Adnexus Therapeutics, Alanex, Ciphergen, CoCensys, Gryphon Sciences, Nova, NPS and Sepracor in the USA, and AkuBio, Astex Therapeutics, BioVex, Lorantis, and Santhera in Europe; he served as chair of the technology transfer strategy panel of the Wellcome Trust from 2002 to 2008. Dr Rink was President and Chief Technical Officer of Amylin Pharmaceuticals Inc. from 1990 to 1995, and was Vice-President for Research at SmithKline from 1984 to 1989. Prior to this he was a lecturer in physiology at the University of Cambridge. He received his MA, MD and ScD degrees from the University of Cambridge.  Rink is former Chairman and Chief Executive Officer of Aurora Biosciences Corporation, a drug discovery technology company in San Diego, California. He is currently a board member of Cambridge Epigenetix Ltd and Genome Research Ltd. Over the past 20 years, Dr Rink has also served on the boards of Adnexus Therapeutics, Alanex, Ciphergen, CoCensys, Gryphon Sciences, Nova, NPS and Sepracor in the USA, and AkuBio, Astex Therapeutics, BioVex, Lorantis, and Santhera in Europe; he served as chair of the technology transfer strategy panel of the Wellcome Trust from 2002 to 2008. Dr Rink was President and Chief Technical Officer of Amylin Pharmaceuticals Inc. from 1990 to 1995, and was Vice-President for Research at SmithKline from 1984 to 1989. Prior to this he was a lecturer in physiology at the University of Cambridge. He received his MA, MD and ScD degrees from the University of Cambridge.

fermentation